Ventria set for Phase III with antibiotic-associated diarrhoea drug
This article was originally published in Scrip
Executive Summary
Ventria Bioscience is to begin Phase III development of its lead therapeutic candidate, VEN100 (recombinant human lactoferrin) for antibiotic-associated diarrhoea (AAD), based on a Phase II trial showing that the product can nearly halve the incidence of antibiotic-associated diarrhoea in high-risk patients.